Post-transplant lymphoproliferative disease of donor origin, following haematopoietic stem cell transplantation in a patient with blastic plasmacytoid dendritic cell neoplasm.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare condition that originates from dendritic cells. We report on the first case of Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disorder (PTLD) of donor origin in a BPDC patient post-allogeneic haematopoietic stem cell transplantation (HSCT). Flow cytometry study identified a cell population CD4+/CD56+/CD45RA+/CD123+/TCL1+ suggestive of BPDCN diagnosis, which was confirmed by a lymph node biopsy (cells positive for BCL11a, BDCA-2, CD2AP, CD123, TCL1 and S100). Cytogenetic analysis revealed a complex karyotype: (19 metaphase) 47,XX,t(1;6)(q21;q2?5),-13 + 2mar[11]/47, XX, +21 [3]/46,XX [5]. The patient was started on acute myeloid leukaemia (AML) induction schedule, and subsequently an allogeneic HSCT was performed. On day +36 post-HSCT, bone marrow biopsy/aspirate showed complete morphological remission, and chimerism study showed 100% donor chimera. However, on day +37, the patient was found to have enlarged cervical and supraclavicular lymphoadenopathy, splenomegaly and raised lactic dehydrogenase. EBV-DNA copies in blood were elevated, consistent with a lytic cycle. A lymph node biopsy showed EBV encoded RNA and large atypical B cells (CD45dim-, CD4+/CD56+, monoclonal for k-chain, CD19+/CD20+/CD21+/CD22+/CD38+/CD43+/CD79β-/CD5-/CD10-), consistent with PTLD monomorphic type. Chimerism study showed that PTLD was of donor origin. This case together with the recent literature findings on BPDCN and PTLD are discussed.
Haematology Dept, San Maurizio Regional Hospital, Bolzano, South Tyrol, Italy. apiccin@gmail.com
Andrea
A
Piccin
Enrico
E
Morello
Mirija
M
Svaldi
Torsten
T
Haferlach
Fabio
F
Facchetti
Giovanni
G
Negri
Cinzia
C
Vecchiato
Simona
S
Fisogni
Irene
I
Pusceddu
Sergio
S
Cortelazzo
D000328:Adult; D003713:Dendritic Cells / Q000473:pathology* / Q000821:virology; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000628:therapy / Q000821:virology; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications* / Q000628:therapy / Q000821:virology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D004854:Herpesvirus 4, Human / Q000472:pathogenicity; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy; D008297:Male; D054219:Neoplasms, Plasma Cell / Q000150:complications* / Q000628:therapy / Q000821:virology; D011379:Prognosis; D012074:Remission Induction; D012878:Skin Neoplasms / Q000150:complications* / Q000628:therapy / Q000821:virology; D014184:Transplantation, Homologous